---

Molnupiravir and Sotrovimab

Answer

The response on 21 June 2022 referred to data from clinical trials conducted in 2021 that informed the decision to procure these treatments and to make them available on the National Health Service.

This data being referred to in June included, for example, the EPIC-HR trial, for which results showed an 89% reduction in hospitalisation or death from Paxlovid compared to a placebo when administered within three days of symptom onset. Results from the MOVe-Out trial indicate molnupiravir reduces the relative risk of hospitalisation or death by 30% compared to placebo.

A 2021 trial courtesy of Gottlieb et al. showed that among non-hospitalised patients at high risk for COVID-19 progression, a three-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.

Interim analysis of the COMET-ICE showed that a single dose of the monoclonal antibody sotrovimab was found to reduce the risk of hospitalisation and death by 79% in high-risk adults with symptomatic COVID-19 infection. There is, however, uncertainty whether the omicron variant has any impact on sotrovimab’s effectiveness, but the Medicines and Healthcare products Regulatory Agency are working to establish this.

On 28 November 2022, the NHS published Interim Clinical Commissioning Policy: Treatments for non-hospitalised patients with COVID-19 which summarises the evidence base for clinicians to consider. A copy of this document is attached.

Secondary information

Type

Written question

Reference

HL4913

Session

2022-23

Attachment

Interim Clinical Commissioning Policy: Treatments

Related items

Molnupiravir and Sotrovimab
Tuesday, 21 June 2022
Written questions
House of Lords

Subjects

Medical treatments Research Coronavirus Immunosuppression Molnupiravir Sotrovimab

Link

View this Written question on www.parliament.uk